1. Signaling Pathways
  2. Neuronal Signaling
  3. Transthyretin (TTR)

Transthyretin (TTR)

thyroxine-binding prealbumin

Transthyretin (TTR), formerly known as thyroxine-binding prealbumin, is a tetrameric protein transporting hormones in the plasma and brain. It forms a complex with retinol-binding protein (RBP), which facilitates the transport of thyroid hormones and vitamin A in the blood and cerebrospinal fluid. TTR is a positive indicator of nutrition status and is negatively correlated with inflammation. TTR is a neuroprotective and oxidative-stress-suppressing factor. The TTR structure is destabilized by mutations, oxidative modifications, aging, proteolysis, and metal cations, including Ca2+. Destabilized TTR molecules form amyloid deposits, resulting in senile and familial amyloidopathies.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-14852
    Tafamidis
    99.89%
    Tafamidis is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. Tafamidis inhibits amyloidogenesis.
    Tafamidis
  • HY-132609
    Patisiran sodium
    Patisiran sodium is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran sodium specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran sodium can be used for the research of hereditary TTR amyloidosis.
    Patisiran sodium
  • HY-107633
    A 1120
    99.42%
    A 1120 is a high-affinity nonretinoid retinol-binding protein 4 (RBP4) antagonist with a Ki value of 8.3 nM. A 1120 disrupts the interaction between RBP4 and its binding partner transthyretin.
    A 1120
  • HY-109165A
    Acoramidis hydrochloride
    98.70%
    Acoramidis (AG10) hydrochloride is an orally active and selective kinetic stabilizer of WT and V122I-TTR (transthyretin). Acoramidis (AG10) hydrochloride is used in the study for transthyretin amyloidosis.
    Acoramidis hydrochloride
  • HY-132589
    Vutrisiran
    Vutrisiran (ALN-TTRsc02) is a liver-directed, investigational, small interfering ribonucleic acid (siRNA) agent. Vutrisiran can be used for transthyretin (TTR)-mediated amyloidosis research.
    Vutrisiran
  • HY-148089A
    Eplontersen sodium
    Inhibitor
    Eplontersen sodium is a triantennary N-acetyl galactosamine (GalNAc3-7a)-conjugated antisense oligonucleotide targeting transthyretin (TTR) mRNA to inhibit production of both variant and wild-type TTR protein. Misfolded TTR induces amyloid fibrils formation in the heart and peripheral nerves, leads to amyloid TTR (ATTR) amyloidosis diseases.
    Eplontersen sodium
  • HY-132590A
    Revusiran sodium
    Inhibitor
    Revusiran sodium is a 1st-generation short interfering RNA, which directed against transthyretin (TTR) mRNA. Revusiran sodium can be used for transthyretin (TTR)-mediated amyloidosis research.
    Revusiran sodium
  • HY-155299
    PITB
    Inhibitor
    PITB is a selective and orally active transthyretin (TTR) aggregation inhibitor. PITB can be used for transthyretin amyloidosis (ATTR) disease research.
    PITB
  • HY-14852A
    Tafamidis meglumine
    99.52%
    Tafamidis meglumine (Fx-1006A) is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. Tafamidis meglumine inhibits amyloidogenesis.
    Tafamidis meglumine
  • HY-132608
    Inotersen sodium
    Inotersen (ISIS-420915) sodium is a 2′-O-methoxyethyl-modified antisense oligonucleotide. Inotersen sodium inhibits the production of transthyretin (TTR) protein by targeting the TTR RNA transcript and reduces the levels of the TTR transcript. Inotersen sodium can be used for the research of hereditary TTR amyloidosis polyneuropathy.
    Inotersen sodium
  • HY-153609
    AS-Patisiran sodium
    Inhibitor
    AS-Patisiran sodium is an antisense strand of Patisiran. Patisiran is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran can be used for the research of hereditary TTR amyloidosis.
    AS-Patisiran sodium
  • HY-153577
    WT-TTR inhibitor 1
    Inhibitor 98.03%
    WT-TTR inhibitor 1 (Compound 21) is a wild-type Transthyretin (WT-TTR) inhibitor with 29.05% inhibition at 100 μM.
    WT-TTR inhibitor 1
  • HY-113950
    Dichlorophenyl-ABA
    ≥99.0%
    Dichlorophenyl-ABA is an inhibitor of transthyretin (TTR) amyloid fibril formation, inhibiting aggregate formation in more than 80% in TTR L55P-expressing cells.
    Dichlorophenyl-ABA
  • HY-109165
    Acoramidis
    Acoramidis (AG10) is an orally active and selective kinetic stabilizer of WT and V122I-TTR (transthyretin). Acoramidis (AG10) is used in the study for transthyretin amyloidosis.
    Acoramidis
  • HY-148089
    Eplontersen
    Inhibitor
    Eplontersen is a triantennary N-acetyl galactosamine (GalNAc3-7a)-conjugated antisense oligonucleotide targeting transthyretin (TTR) mRNA to inhibit production of both variant and wild-type TTR protein. Misfolded TTR induces amyloid fibrils formation in the heart and peripheral nerves, leads to amyloid TTR (ATTR) amyloidosis diseases.
    Eplontersen
  • HY-14852S
    Tafamidis-d3
    Tafamidis-d3 is deuterium labeled Tafamidis. Tafamidis is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. Tafamidis inhibits amyloidogenesis[1].
    Tafamidis-d<sub>3</sub>
  • HY-112974
    Inotersen
    Inhibitor
    Inotersen is an antisense oligonucleotide that inhibits hepatic production of transthyretin (TTR).
    Inotersen
  • HY-146137
    Transthyretin-IN-1
    Transthyretin-IN-1 (Compound 1d) is a transthyretin (TTR) fibril formation inhibitor. Transthyretin-IN-1 can be used for Alzheimer’s disease research.
    Transthyretin-IN-1
  • HY-132590
    Revusiran
    Revusiran (ALN-TTRSC) is a 1st-generation short interfering RNA, which directed against transthyretin (TTR) mRNA. Revusiran can be used for transthyretin (TTR)-mediated amyloidosis research.
    Revusiran
  • HY-160612
    Transthyretin-IN-2
    Inhibitor
    Transthyretin-IN-2 (Compound 36) is a transthyretin (TTR) amyloidsis inhibitor, with IC50 and pIC50 values of 1.31 μM and 5.88 μM. Transthyretin-IN-2 can be used for the research of TTR amyloidosis diseases.
    Transthyretin-IN-2
Cat. No. Product Name / Synonyms Application Reactivity